Claims
- 1. A method of administering a compound of the formula
- 2. A method according to claim 1 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin; cyclophosphamide; 5-fluorouracil, doxorubicin and taxol.
- 3. A method according to claim 1 wherein the compound is selected from the group consisting of:
- 4. A method according to claim 3 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
- 5. A method of treating or preventing a neoplasia disease comprising administering to a mammal in need of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:
- 6. A method according to claim 5 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
- 7. A method according to claim 5 wherein the compound is selected from the group consisting of
- 8. A method according to claim 7 wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, 5-fluorouracil, doxorubicin and taxol.
- 9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, a chemotherapeutic agent and a pharmaceutically acceptable carrier.
- 10. A method according to claim 5 wherein the neoplasia disease is tumor metastasis.
- 11. A method according to claim 5 wherein the neoplasia disease treated is solid tumor growth.
- 12. A method according to claim 5 wherein the condition treated is angiogenesis.
- 13. A method according to claim 5 wherein the neoplasia disease is humoral hypercalcemia of malignancy.
Parent Case Info
[0001] The present application claims priority from U.S. Ser. No. 09/034,270 filed Mar. 4, 1998.
Continuations (1)
|
Number |
Date |
Country |
Parent |
09262725 |
Mar 1999 |
US |
Child |
10016146 |
Dec 2001 |
US |